A. K. Das, Sanjay Kalra¹, Shahid Akhtar², Raman Shetty², Ajay Kumar³
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, ¹Department of Endocrinology, Bharti Hospital and B.R.I.D.E, Kamal, Haryana, ²Novo Nordisk India Private Limited, Bengaluru, Karnataka, ³Diabetes Care and Research Centre, Patna, Bihar, India

ABSTRACT

Aim: The aim of the following study is to evaluate the safety and effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp 30) in Indian patients with type 2 diabetes as a sub-analysis of the 24-week, non-interventional A chinese study. Materials and Methods: Indian patients switching from BHI to BIAsp 30 based on the physicians’ decisions were included. The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycemic events; secondary outcomes included changes in hypoglycemia in the 4 weeks preceding baseline and week 24 and changes from baseline to week 24 in glycated hemoglobin A₁c (HbA₁c), fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), body weight and quality of life (QoL). Results: Overall, 1976 patients (mean ± standard deviation age, 55.1 ± 10.6 years and diabetes duration, 10.1 ± 5.3 years) on a mean pre-study BHI dose of 0.44 ± 0.18 U/kg were included. The mean BIAsp 30 dose was 0.43 ± 0.17 U/kg at baseline and 0.44 ± 0.17 U/kg at week 24. No SADRs were reported. The proportion of patients reporting overall hypoglycemic events reduced significantly from baseline to week 24 (15.0% vs. 2.9%, P < 0.0001). The mean HbA₁c level improved significantly from 9.1 ± 1.4% at baseline to 7.5 ± 1.0% at week 24 (15.0% vs. 2.9%, P < 0.0001). The mean body weight decreased from 69.3 ± 10.8 kg at baseline to 69.1 ± 10.4 kg at week 24 (P = 0.003). Conclusion: Switching from BHI to BIAsp 30 therapy was well-tolerated and was associated with improved glycemic control.

Key words: Biphasic human insulin, biphasic insulin aspart 30, India, type 2 diabetes

INTRODUCTION

Type 2 diabetes (T2D) is a major health predicament in the Indian subcontinent. According to the International Diabetes Federation, India had approximately 61.3 million adults with diabetes in 2011 and is predicted to have 101.2 million diabetes patients by 2030.¹ This estimate implies that around 2 million new cases of diabetes would be diagnosed every year in India.¹ A difference in T2D prevalence has also been noted between the urban and rural populations in India (11.6% and 2.4%, respectively).²

Alleviating the T2D burden is of paramount importance as diabetes causes many severe long-term complications including kidney failure, cardiovascular disease and retinal complications. It is imperative to effectively intensify treatment strategies for T2D in the primary care setting,³ however, patient compliance to intensified therapy, including insulin, is often compromised due to fears of hypoglycemia, weight gain and the perceived inability to lead a normal life.

Biphasic insulin formulations combine rapid-acting insulin with a longer-acting protaminated variant, thereby
Das, et al.: Switch from BHI to BIAsp 30: Achieve India

providing both mealtime and post-meal control of blood glucose levels. Such preparations also have the benefit of requiring fewer injections compared with a traditional basal-bolus insulin regimen and therefore offer more convenient and simpler options for dosing.

Biphasic insulin aspart 30 (BIAsp 30) is an insulin analogue preparation consisting of insulin aspart and protamine insulin aspart in a 30:70 ratio. Studies have reported that BIAsp 30, in comparison to biphasic human insulin (BHI), lowers glycated hemoglobin $A_1c$ ($HbA_1c$) to a similar or greater extent and is associated with better control of postprandial plasma glucose (PPPG) levels. Lowering PPPG levels is known to have important effects on improving general cardiovascular health and minimizing vascular risks. Improved patient outcomes in the long-term could therefore well be contingent upon an insulin regimen that can deliver effective PPPG control. The risks of major hypoglycemia (hypoglycemic events associated with a blood glucose level of $<56$ mg/dL that the patient is unable to self-treat) and nocturnal hypoglycemia are also reported to be lower with BIAsp 30 than with BHI.

In the multinational Achieve study, the use of insulin analogues to treat T2D patients was examined across 28 countries. Results from the overall Achieve cohort that switched from BHI therapy to BIAsp 30 have been published previously, as have the results from the entire Indian cohort initiating or switching to BIAsp 30. This sub-analysis of the Indian cohort aimed to determine whether patients with poorly controlled T2D on BHI could be benefitted by changing therapy to BIAsp 30.

**Materials and Methods**

**Study design**

Achieve was a 24-week, prospective, open-label, non-interventional study conducted across four continents to examine the safety and effectiveness of BIAsp 30 (NovoMix® 30, Novo Nordisk A/S), insulin detemir (Levemir®, Novo Nordisk A/S) and insulin aspart (NovoRapid®, Novo Nordisk A/S), alone or in combination with basal insulin, in clinical practice. This subgroup analysis was performed in Indian patients with T2D who changed therapy to BIAsp 30 from BHI.

Patients were recruited from 621 centers in India between May 2009 and December 2010. The decision to switch from BHI to BIAsp 30 therapy was made by the consulting physicians who also decided the dose and dosing frequency throughout the study. BIAsp 30 was available locally and was used in accordance with the locally approved label. Concomitant oral glucose-lowering drugs (OGLDs) were also permitted at the discretion of the physician.

Data were recorded in the standard case report forms from the physicians’ notes and the patients’ diaries and blood glucose meters.

**Selection criteria**

Patients who had changed therapy from BHI to BIAsp 30 within 4 weeks prior to starting the study were included in this subgroup analysis.

Any patient with known allergies or hypersensitivity to the study drug or any of the excipients was excluded. Pregnant or lactating women and those who planned to become pregnant within 6 months of starting the study were also excluded. The study was approved by the Local Ethics Committee in India and all patients provided informed consent for study participation.

**Study assessments and endpoints**

There were no special investigative procedures in this study; all assessments were carried out by the consulting physicians at routine visits (baseline, week 12 and week 24) to the local clinics.

The primary endpoint was the occurrence of serious adverse drug reactions (SADRs), including major hypoglycemia, over 24 weeks. Secondary safety endpoints included the occurrence of serious adverse events (SAEs) over 24 weeks and the change in the frequency of hypoglycemic events in the 4 weeks preceding baseline and week 24.

Efficacy endpoints comprised the change from baseline to week 24 in $HbA_1c$, fasting plasma glucose (FPG), PPPG, total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, systolic blood pressure (SBP) and body weight. Laboratory parameters were subject to local standardization and quality control.

In addition, quality of life (QoL) was assessed using the EuroQol-5 dimension (EQ-5D) questionnaire and the EuroQoL visual analog scale (EQ-VAS). The EQ-5D questionnaire covers five health dimensions (anxiety/depression, mobility, pain/discomfort, self-care and usual activity), whereas the EQ-VAS rates a patient’s current health state from 0 (worst score) to 100 (best score).

**Statistical analysis**

Statistical analyses were performed for the subgroup of Indian patients switching from pre-study BHI therapy to BIAsp 30. Continuous variables were summarized using descriptive statistics (mean, median, standard deviation [SD]) and discrete variables were summarized using frequency tables ($n$, %).
The change from baseline to week 24 in HbA1c, FPG, PPPG, lipids, body weight, SBP and QoL was analyzed using a paired t-test. The difference from baseline to week 24 in the proportion of patients reporting at least one hypoglycemic event was analyzed using McNemar’s test. Two-sided tests were used and statistical significance was pre-defined at the 5% level.

All analyzes were performed by Novo Nordisk using SAS® Version 9.1.3.

RESULTS

General characteristics
A total of 1976 patients switched therapy from pre-study BHI to BIAsp 30 in the Indian cohort [Table 1]. These patients had a mean ± SD age of 55.1 ± 10.6 years, body mass index of 25.9 ± 3.7 kg/m² and had T2D for 10.1 ± 5.3 years. The average duration on insulin was 3.0 ± 2.6 years for these patients.

The most frequently reported physicians’ reasons for changing therapy were to improve glycemic control (95.5% of patients) and to reduce the risk of hypoglycemia (40.3% of patients).

At baseline, 83.8% of patients were taking metformin and 59.1% were taking sulfonylureas concomitantly with BIAsp 30 therapy [Table 1].

Daily insulin dose and frequency of dosing
The mean total BHI dose by weight was 0.44 ± 0.18 U/kg at pre-study [Table 2]. Patients started on a mean total BIAsp 30 dose of 0.43 ± 0.17 U/kg at baseline and had a mean dose of 0.44 ± 0.17 U/kg by the end of the study. The mean total daily insulin doses at pre-study, baseline and week 24 are presented in Table 2.

At pre-study, 83.3% of patients were taking BHI twice daily (bid). At baseline and week 24, 87.4% and 90.3% of patients, respectively, dosed BIAsp 30 bid.

SADR}s and SAEs
No SADR}s were reported in this subgroup during the study.

Four SAEs were reported (abdominal pain, vomiting, diarrhea and angioplasty), all considered unlikely to be related to BIAsp 30 therapy.

Hypoglycemia
The incidence of overall hypoglycemia was 4.15 events per patient-year at baseline and 0.56 events per patient-year at week 24 [Table 3]. The proportion of patients reporting at least one event of overall hypoglycemia significantly decreased from baseline to week 24 (15.0% vs. 2.9%, P < 0.0001).

| Table 1: Demographic and baseline characteristics of patients switching from BHI to BIAsp 30 |
|-----------------------------------------------|
| All patients                                    |
| N                                         | 1976 |
| Male, %                                      | 66.9 |
| Female, %                                    | 33.1 |
| Age± years                                   | 55.1 (10.6) |
| Body weight*, kg                             | 69.8 (11.1) |
| Body mass index*, kg/m²                      | 25.9 (3.7) |
| Duration of diabetes*, years                 | 10.1 (5.3) |
| Duration on insulin*, years                  | 3.0 (2.6) |
| OGLDs at baseline, n (%)                     | 1146 (83.8) |
| Metformin                                    | 1088 (59.1) |
| Sulfonylurases                                | 164 (12.0) |
| Thiazolidinediones                            | 164 (12.0) |
| One OGLD                                     | 560 (41.0) |
| Two OGLDs                                    | 666 (44.3) |
| >Two OGLDs                                   | 201 (14.7) |
| *Data are mean (SD). BHI: Biphasic human insulin, BIAsp 30: Biphasic insulin aspart 30, OGLDs: Oral glucose-lowering drugs, SD: Standard deviation |

| Table 2: Insulin dose and dosing frequency at pre-study, baseline and week 24 |
|-----------------------------------------------|
| All patients                                    |
| Insulin dose, U/kg n                          | 1898 |
| Pre-study*                                    | 0.44 (0.18) |
| Baseline*                                     | 0.43 (0.17) |
| Week 24*                                      | 0.44 (0.17) |
| Insulin dose, U/day n                         | 1976 |
| Pre-study*                                    | 30.0 (11.8) |
| Baseline*                                     | 29.5 (10.9) |
| Week 24*                                      | 29.6 (11.1) |
| Daily dose frequency                          | 1976 |
| Pre-study, n                                  | 168 (8.5) |
| Once, n (%)                                   | 1646 (83.3) |
| Twice, n (%)                                  | 162 (8.2) |
| >Thrice, n (%)                                | 1 (0.1) |
| Baseline, n                                   | 1556 |
| Once, n (%)                                   | 127 (8.2) |
| Twice, n (%)                                  | 1405 (90.3) |
| Thrice, n (%)                                  | 22 (1.4) |
| >Thrice, n (%)                                | 2 (0.1) |
| *Pre-study, baseline and week 24 values are mean (SD). SD: Standard deviation |

| Table 3: Baseline and week 24 data for hypoglycemia |
|-----------------------------------------------|
| Hypoglycemia (event per patient-year/percent with at least one event) |
| Baseline | Week 24 | P value |
| Overall | 4.15 / 15.0 | 0.56 / 2.9 | <0.0001 |
| Major | 0.49 / 3.2 | 0.0 / 0.0 | <0.0001 |
| Minor | 3.66 / 14.3 | 0.56 / 2.9 | <0.0001 |
| Nocturnal | 1.21 / 7.0 | 0.12 / 0.6 | <0.0001 |
| P value is from McNemar’s test on paired proportions of patients experiencing at least one event |
No major hypoglycemic events were reported at week 24 compared with incidence of 0.49 events per patient-year at decreased from baseline to week 24 (15.0% vs. 2.9%, P < 0.0001).

No major hypoglycemic events were reported at week 24 compared with incidence of 0.49 events per patient-year at baseline [Table 3]. The difference from baseline to week 24 in the proportion of patients reporting at least one event of major hypoglycemia was significant (P < 0.0001).

Significant decreases from baseline to week 24 were also noted in the proportions of patients reporting at least one event of minor hypoglycemia (14.3-2.9%) and nocturnal hypoglycemia [7.0-0.6%, both P < 0.0001, Table 3].

**Glycemic parameters**

From baseline to week 24, the mean HbA<sub>1c</sub> level reduced significantly from 9.1 ± 1.4% to 7.5 ± 1.0% [P < 0.001, Table 4]. At week 24, 394 patients had HbA<sub>1c</sub> levels of <7.0% compared with 52 patients at baseline.

The mean FPG level significantly reduced from 186.3 ± 54.4 mg/dL at baseline to 127.5 ± 36.9 mg/dL at week 24 and the mean post-breakfast PPPG significantly reduced from 274.0 ± 74.2 mg/dL to 200.7 ± 60.0 mg/dL during the same time [both P < 0.001, Table 4].

**Lipids**

Significant reductions were observed in the mean total cholesterol, triglyceride and LDL cholesterol levels over 24 weeks [all P < 0.001, Table 5]. There was no statistically significant change in the mean HDL cholesterol level from baseline to week 24.

**Body weight and SBP**

The mean body weight was 69.3 ± 10.8 kg at baseline and 69.1 ± 10.4 kg at week 24 [P = 0.003, Table 5]. The mean SBP also reduced significantly from 135.6 ± 16.0 kg at baseline to 128.4 ± 11.8 kg at week 24 [P < 0.001, Table 5].

**QoL**

Patient-reported QoL increased significantly from 55.0 ± 9.8 points at baseline to 72.8 ± 9.3 points at week 24 as measured by the EQ-VAS (P < 0.001).

From baseline to week 24, the proportion of patients reporting no problems in the five dimensions of the EQ-5D questionnaire also appeared to increase (anxiety/depression: 43.3% vs. 81.5%; mobility: 41.2% to 86.9%; pain/discomfort: 36.2% vs. 76.2%; self-care: 40.2% vs. 68.4%; usual activity: 36.1% to 73.5%).

**Discussion**

This subgroup analysis demonstrated that switching from pre-study BHI to BIAsp 30 therapy was well-tolerated and resulted in improvements in glycemic parameters for T2D patients in local clinical practice in India. No SADRs were reported in this subgroup. Furthermore, there was a significant decline from baseline to week 24 in the proportion of patients reporting at least one event of overall hypoglycemia.

Poor glycemic control was apparent in this subgroup at baseline. Patients had been taking insulin for an average of 3 years, with or without OGLDs; however, the mean baseline HbA<sub>1c</sub> level was 9.1%, well above the international clinical recommendation of <7.0%. Following the therapy switch from BHI to BIAsp 30, the mean HbA<sub>1c</sub> improved significantly, along with significant reductions in the mean FPG and post-breakfast PPPG levels and a low incidence of overall hypoglycemia at week 24 (0.56 events/patient-year). El Naggar et al.[11] have also reported improved glycemic control and low incidences of hypoglycemia in the overall A<sub>c</sub>ieve cohort that switched to BIAsp 30 therapy from BHI. Sub-analyses from the improve and present

---

**Table 4: Baseline and 24-weeks data for glucose control parameters**

| Parameter | n  | Baseline | Week 24 | Change  | P value |
|-----------|----|----------|---------|---------|---------|
| HbA<sub>1c</sub>, % | 1434 | 9.1 (1.4) | 7.5 (1.0) | -1.6 (1.3) | <0.001 |
| FPG, mg/dL | 1352 | 186.3 (54.4) | 127.5 (36.9) | -58.8 (54.2) | <0.001 |
| PPPG, mg/dL | 844 | 274.0 (74.2) | 200.7 (60.0) | -73.3 (73.7) | <0.001 |

Baseline, week 24 and change values are mean (SD). FPG: Fasting plasma glucose, HbA<sub>1c</sub>: Glycated hemoglobin A<sub>c</sub>, PPPG: Postprandial plasma glucose, SD: Standard deviation.

**Table 5: Baseline and 24-week data for lipids, body weight and SBP**

| Parameter | n  | Baseline | Week 24 | Change  | P value |
|-----------|----|----------|---------|---------|---------|
| Total cholesterol, mmol/L | 230 | 5.2 (0.8) | 4.8 (0.7) | -0.4 (0.5) | <0.001 |
| Triglycerides, mmol/L | 427 | 2.0 (0.8) | 1.8 (0.6) | -0.2 (0.5) | <0.001 |
| HDL cholesterol, mmol/L | 437 | 1.0 (0.2) | 1.0 (0.3) | -0.0 (0.2) | 0.125 |
| LDL cholesterol, mmol/L | 430 | 2.9 (0.9) | 2.7 (0.7) | -0.3 (0.7) | <0.001 |
| Body weight, kg | 1409 | 69.3 (10.8) | 69.1 (10.4) | -0.2 (2.2) | 0.003 |
| SBP, mmHg | 1092 | 135.6 (16.0) | 128.4 (11.8) | -7.2 (13.2) | <0.001 |

Baseline, week 24 and change values are mean (SD). P values are not presented when the number of patients analyzed was <100. HDL: High-density lipoprotein, LDL: Low-density lipoprotein, SBP: Systolic blood pressure, SD: Standard deviation.
observational studies also demonstrated that switching to BIAsp 30 therapy from BHI was associated with significantly ameliorated glycemic control as well as a reduced risk of hypoglycemia in T2D patients. Significant improvements in mean HbA1c were also noted in patients who switched from BHI 30 or 50 to BIAsp 30, 50 or 70 in routine clinical practice in another 26 weeks observational study.

The improvements in glycemic parameters were obtained without a substantial increase in the mean BIAsp 30 dose levels from baseline to week 24. A retrospective study in the United Kingdom found that effective reductions in HbA1c could be obtained with lower doses of BIAsp compared with BHI 30 in patients with T2D. These results could potentially have important implications for developing countries such as India where medication costs would also be a key factor in the choice of treatment. The majority of patients followed bid dosing of BIAsp 30 and 394 patients achieved the HbA1c target at the end of the study. Further, BIAsp 30 tid dosing can also be effective for patients who are unable to attain glycemic targets with bid dosing, as demonstrated in the 1-2-3 study.

Significantly lower total cholesterol, triglyceride and LDL cholesterol levels were noted at week 24 compared with baseline, along with significant improvements in SBP levels in this subgroup. A retrospective review of data from patients with T2D previously treated with BHI noted that lipid levels and blood pressure (systolic and diastolic) improved over 6 months after switching to BIAsp 30 therapy. Ohira et al. have reported improvements in arterial stiffness, which is known to be associated with coronary atherosclerosis, in a group of 26 T2D patients 3 months after switching from BHI 30 to BIAsp 30. High PPPG levels are known to be correlated with increased cardiovascular dysfunction; hence, it is feasible that the improvements in PPPG obtained with BIAsp 30 therapy could also positively impact cardiovascular outcomes.

There was a small reduction in mean body weight from 69.3 ± 10.8 kg at baseline to 69.1 ± 10.4 kg at week 24 in this subgroup (P = 0.003) in contrast to findings from a 12-month comparative study, which indicated that BIAsp 30 and BHI therapy displayed similar effects on weight increase. It is possible that enrolment in the Acheive India study may have prompted patients to embrace positive life-style changes, which in turn could have led to the lower mean body weight seen at week 24 in the Indian subgroup.

Hypoglycemia and the other co-morbidities associated with T2D are known to deteriorate QoL. In this sub-analysis, significant improvements in QoL after 24 weeks were noted based on the EQ-VAS ratings. Furthermore, patients appeared to have fewer problems with anxiety/depression, mobility, pain/discomfort, self-care and usual activity at week 24 compared with baseline as measured by the EQ-5D questionnaire.

The absence of a control group could potentially have introduced bias in this study. It is possible that the findings could be attributed to a study effect as most of the safety and effectiveness parameters were based on patient recall, diaries or self-reported information. Data for hypoglycemia were recorded based on the patient’s recall of the hypoglycemic events that occurred in the 4 weeks prior to the study visits. Furthermore, no information was collected on the patients’ diet and concomitant medication during the study. However, despite these limitations, glycemic control improved in this subgroup following the switch to BIAsp 30 therapy from pre-study BHI. Importantly, BIAsp 30 therapy was not associated with any SADRs during the study.

**Conclusion**

The results from this sub-analysis suggest that patients poorly controlled on BHI could be benefitted by switching to a BIAsp 30 regimen with or without OGLDs.

**References**

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
2. Ramachandran A. Epidemiology of type 2 diabetes in Indians. J Indian Med Assoc 2002;100:425-7.
3. Engelgau MM, Narayan KM, Saaddine JB, Vinicor F. Addressing the burden of diabetes in the 21st century: Better care and primary prevention. J Am Soc Nephrol 2003;14 7 Suppl 2:S88-91.
4. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human? Diabetes Obes Metab 2007;9:630-9.
5. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004;15:496-502.
6. Veloric-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest 2009;32:23-7.
7. Qayyum R, Wilson LM, Boelen S, Maruthur N, Marinopoulos SS, Feldman L, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes. Rockville, MD: Agency for Healthcare Research and Quality (US); 2008. (Comparative Effectiveness Reviews, No. 14.).
8. Gallwitz B. Implications of postprandial glucose and weight control in people with type 2 diabetes: Understanding and implementing the International diabetes federation guidelines. Diabetes Care 2009;32 Suppl 2:S322-5.
9. Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with...
type 2 diabetes mellitus: A meta-analysis. Clin Ther 2009;31:1641-51.
10. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chalikarwar P, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries. The A1chieve study. Diabetes Res Clin Pract 2011;94:352-63.
11. El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study. Diabetes Res Clin Pract 2012;98:408-13.
12. Kumar A, Sharma SK, Rajput R, Unnikrishnan AG. Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study. J Assoc Physicians India 2013;61:16-20.
13. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96.
14. Shah S, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, et al. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: Subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract 2009;63:574-82.
15. Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: Experiences from the PRESENT study. Curr Med Res Opin 2007;23:3209-14.
16. Nobels F, D’Hooge D, Crenier L. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: Observational study results. Curr Med Res Opin 2012;28:1017-26.
17. Fakhoury WK, Richter H, Christensen TE. Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes. Adv Ther 2010;27:859-69.
18. Garber AJ, Wahren J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66.
19. Gero L, Gyimesi A, Hidvégi T, Jánosi I. Improvement in glycaemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart. Orv Hetil 2009;150:1637-47.
20. Ohira M, Endo K, Oyama T, Yamaguchi T, Ban N, Kawana H, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 2011;60:78-85.
21. Temizel M, Mert M, Bozbey C, Arman Y, Cevizci E, Altintas N, et al. Evaluation of the weight-increasing effects of biphasic analog and regular NPH insulin mixtures in patients with Type 2 diabetes mellitus. J Diabetes 2010;2:250-5.
22. Sheu WH, Ji LN, Nitiyanant W, Baik SH, Yn D, Mavros P, et al. Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Res Clin Pract 2012;96:141-8.
23. Green AJ, Bazata DD, Fox KM, Grandy S. Quality of life, depression, and healthcare resource utilization among adults with type 2 diabetes mellitus and concomitant hypertension and obesity: A prospective survey. Cardiol Res Pract 2012;2012:404107.